Research programme: tissue factor/factor VIIa complex inhibitors - BioCryst/Sunol Molecular

Drug Profile

Research programme: tissue factor/factor VIIa complex inhibitors - BioCryst/Sunol Molecular

Alternative Names: BCX 3607; BCX 3891

Latest Information Update: 02 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals; Sunol Molecular Corporation
  • Developer BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Factor VIIa inhibitors; Thromboplastin inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Coronary disorders; Thrombosis

Most Recent Events

  • 31 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the Thromboses pharmacodynamics section
  • 01 Sep 2004 Preclinical trials in Cancer in USA (PO)
  • 09 May 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top